Confo Therapeutics receives €1.7 million grant from VLAIO
VUB-VIB spin-off and emerging drug discovery company Confo Therapeutics has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the company’s proprietary pre-clinical programs, targeting a neurological orphan indication.
Cedric Ververken, CEO of Confo Therapeutics: “This new grant will allow us to progress novel GPCR-modulating compounds against a neurological orphan indication further into pre-clinical development. We are excited about the potential of our approach to treating this particular indication and are grateful to VLAIO for its support of this project.”
More info on website Confo Therapeutics.